Le Lézard
Classified in: Health
Subjects: SVY, TRI

Norgine Launches New Discussion Paper - Scope for Change: What Next for European Colonoscopy Services?


AMSTERDAM, September 25, 2017 /PRNewswire/ --

Norgine B.V. today announced it has launched a new discussion paper "Scope for change: what next for European colonoscopy services?" which identifies five key areas that pose challenges for colonoscopy service provision, but also offer significant opportunities to enhance patient care. This represents the first major milestone of Scope for change, a programme designed to ignite debate among the European colonoscopy community.

     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )

Included in the discussion paper is a vision for the future, along with a number of commitments that Norgine intends to take forward to ensure it is making the greatest possible contribution it can to healthcare communities in order to improve patients' experiences of care, and crucially to save lives.

Key areas:

  1. Improving quality: how do we address variations in the quality of services, both within and between European countries?
  2. Expanding access: how can we ensure access to high-quality colonoscopy services in a timely manner and at a location close to home for all patients who need them?
  3. Changing perceptions: how can we improve understanding of the importance of colonoscopy and encourage people to take up the opportunity for screening?
  4. Embracing technology and medical innovation: how do we boost innovation and spread technological advances?
  5. Ensuring funding: how should the community plan and invest to ensure sustainable colonoscopy services for patients today and in the future?

Dr Alastair Benbow, Chief Development and Medical Officer at Norgine said: "This paper is a clear commitment to build on Norgine's long-established heritage in the area of colonoscopy. It reinforces our continuing work in partnership with the healthcare and patients' communities, now and in the future."

He added: "Over the past decades, Norgine's innovations have significantly advanced patient care by improving bowel cleansing quality - an important factor for detecting adenomas and polyps. We want every patient who needs bowel investigation to have quicker access to a range of innovative diagnostic tools, treatments, and medical technologies, which ultimately prevent diseases at an early stage and save lives."

Norgine reflected on the insights garnered during a pan-European colonoscopy listening exercise completed earlier this year to produce the discussion paper. This involved interviewing over twenty representatives across Europe from stakeholder groups including healthcare professionals, patient groups, policymakers, budget holders, media and the research community.

Media contact: Isabelle Jouin, T: +44(0)1895-453643
Access the full release on http://www.norgine.com


These press releases may also interest you

at 04:24
RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, is celebrating World Lupus Day 2024, which falls on May 10, by sharing the latest developments of the world's first approved dual-target...

at 03:54
On May 9th, Momcozy, a global leader in mother and baby care, hosted a heartwarming event at Babylist Beverly Hills as part of its "Momcozy Village" campaign. This initiative emphasizes the belief that "it takes a village to raise a mother," focusing...

at 03:11
The eighth Aurora Prize for Awakening Humanity was awarded Thursday evening to Dr. Denis Mukwege, a world-renown gynecological surgeon and human rights activist from the Democratic Republic of the Congo (DRC). Dr. Mukwege is the president of Panzi...

at 03:05
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to...

at 03:00
Charging an electric vehicle (EV) at home is certainly more convenient than using a public charging station, but what are the other benefits? Along with convenience, the...

at 02:15
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...



News published on and distributed by: